Clinical Trial Update: Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated alisertib (MLN8237) versus investigator's choice for relapsed or refractory peripheral T-cell lymphoma; the study has completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2018-07-31